Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4906 |
Name | small intestine adenocarcinoma |
Definition | A small intestine carcinoma that derives_from epithelial cells of glandular origin. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer small intestine cancer small intestine carcinoma small intestine adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA H1047X | Bortezomib + Temsirolimus + Topotecan | small intestine adenocarcinoma | predicted - resistant | detail... |
MLH1 mutant | N/A | small intestine adenocarcinoma | not applicable | detail... |
MSH6 mutant | N/A | small intestine adenocarcinoma | not applicable | detail... |
APC mutant | N/A | small intestine adenocarcinoma | not applicable | detail... |
MLH1 negative | Pembrolizumab | small intestine adenocarcinoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | small intestine adenocarcinoma | sensitive | detail... |
MSH6 negative | Nivolumab | small intestine adenocarcinoma | sensitive | detail... |
MLH1 negative | Nivolumab | small intestine adenocarcinoma | sensitive | detail... |
MLH1 negative | Ipilimumab + Nivolumab | small intestine adenocarcinoma | sensitive | detail... |
MSH6 negative | Ipilimumab + Nivolumab | small intestine adenocarcinoma | sensitive | detail... |
MLH1 negative | Dostarlimab-gxly | small intestine adenocarcinoma | sensitive | detail... |
MSH6 negative | Dostarlimab-gxly | small intestine adenocarcinoma | sensitive | detail... |
RET fusion | Selpercatinib | small intestine adenocarcinoma | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | small intestine adenocarcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01202409 | Phase II | Panitumumab | CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater | Completed | USA | 0 |
NCT01208103 | Phase II | Bevacizumab + Capecitabine + Oxaliplatin | Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater | Completed | USA | 0 |
NCT02034110 | Phase II | Dabrafenib + Trametinib | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | Completed | USA | SWE | NOR | NLD | ITA | FRA | ESP | DNK | DEU | CAN | BEL | AUT | 2 |
NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
NCT03000179 | Phase II | Avelumab | Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma | Terminated | USA | 0 |
NCT03095781 | Phase I | Pembrolizumab + XL888 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | Completed | USA | 0 |
NCT03108131 | Phase II | Atezolizumab + Cobimetinib | Cobimetinib and Atezolizumab in Advanced Rare Tumors | Completed | USA | 0 |
NCT04491955 | Phase II | Bintrafusp alfa + CV301 + NHS-IL12 + Nogapendekin alfa inbakicept Bintrafusp alfa + CV301 + Nogapendekin alfa inbakicept | Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers | Completed | USA | 0 |
NCT04729322 | Phase I | Fecal microbiota + Nivolumab Fecal microbiota + Pembrolizumab | Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders | Active, not recruiting | USA | 0 |
NCT06333314 | Phase II | Dostarlimab-gxly Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Doxorubicin Gemcitabine Gemcitabine + Nab-paclitaxel Doxorubicin + Trabectedin Fluorouracil + Leucovorin + Oxaliplatin Cisplatin + Etoposide Cisplatin + Gemcitabine Cisplatin + Doxorubicin + Etoposide Capecitabine + Oxaliplatin Doxorubicin + Ifosfamide Carboplatin + Etoposide Carboplatin + Paclitaxel Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Mitotane | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) | Recruiting | FRA | 0 |